Location Philadelphia, Pennsylvania, United States Regions Greater Philadelphia Area, Great Lakes, Northeastern US Gender Male
LinkedIn View on LinkedIn
Condon joined TetraLogic Pharmaceuticals in 2004 as Director of Chemistry and advanced to Vice President of Research before becoming Chief Scientific Officer. Prior to 2004, Dr. Condon was a Group Leader in medicinal chemistry at ViroPharma Corporation where his team prepared and profiled novel inhibitors of the hepatitis C virus NS5B RNA-dependent
RNA polymerase including HCV-371 which, in collaboration with Wyeth Pharmaceuticals, was selected for clinical development.
From 1995-2000, Dr. Condon was a member of the medicinal chemistry section of Rhône-Poulenc Rorer where his work led to elucidation of the bioactive conformation of human parathyroid hormone (PTH1-34) and the discovery of RPR132561, an anabolic agent for the treatment of post-menopausal osteoporosis. Dr. Condon is an author of over 30 peer-reviewed publications and an inventor on 21 issued US patents. Dr. Condon received his doctoral degree with Professor Amos B. Smith, III at the University of Pennsylvania after completing the total syntheses of rapamycin and demethoxyrapamycin.
